Cross-Sector entity
Of the tracked stories, 2 of 2 also mention American Medical Association, the most common co-covered peer. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Kaiser Permanente San Jose Medical Center appears in 2 tracked Cross-Sector stories from September 13, 2026.
2 verified stories tracked
Last mentioned: Sep 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention American Medical Association, the most common co-covered peer. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Kaiser Permanente San Jose Medical Center appears in 2 tracked Cross-Sector stories from September 13, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kaiser Permanente San Jose Medical Center. Shared-story counts are live from our verified record — not editorial picks.
Updated vaccines available
Updated COVID-19 and flu vaccines become available in the Bay Area.
Bay Area positivity hits 9%
State data show positive COVID-19 tests at moderate levels, slightly more than 9%.
Major SARS-CoV-2 variation emerges
A major viral variation emerges and is later named XFG or Stratus.
Trump administration relaxes COVID-19 vaccine recommendations
Federal recommendations are relaxed, creating widespread confusion in the Bay Area.
Updated COVID-19 and flu vaccines are now available across the Bay Area just as positive tests exceed 9%. Healthcare leaders need clear eligibility guidance and operational readiness for the 2026-27 respiratory season.
The FDA has cleared updated COVID-19 vaccines from Pfizer, Moderna, and Novavax for 2026-27, targeting the XFG/Stratus strain. The decision resets the competitive landscape for seasonal vaccine makers.
Source: eastbaytimes.com · marinij.com
